机构：[1]Department of Orthopaedics, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China[2]Wuhan Children’s Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China[3]Department of Orthopaedics, Xiangyang Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Chinese Medicine, Xiangyang, China[4]Department of Orthopaedics, Wenling First People’s Hospital, Taizhou, China[5]Department of Orthopaedics, Hubei Hospital of Traditional Chinese Medicine, Wuhan, China[6]Department of Orthopaedics, Wuhan Sports University, Wuhan, China
Aptamers are single-stranded nucleic acids (DNA, short RNA, or other artificial molecules) produced by the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technology, which can be tightly and specifically combined with desired targets. As a comparable alternative to antibodies, aptamers have many advantages over traditional antibodies such as a strong chemical stability and rapid bulk production. In addition, aptamers can bind targets in various ways, and are not limited like the antigen-antibody combination. Studies have shown that aptamers have tremendous potential to diagnose and treat clinical diseases. However, only a few aptamer-based drugs have been used because of limitations of the aptamers and SELEX technology. To promote the development and applications of aptamers, we present a review of the methods optimizing the SELEX technology and modifying aptamers to boost the selection success rate and improve aptamer characteristics. In addition, we review the application of aptamers to treat bone diseases.
基金：
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: This
work was supported by the National Natural Science Foundation of
China [grant numbers 81472103]; the Health Family Planning
Research Fund of Wuhan City [grant number WX18M01]; the
Wuhan City ‘Huanghe Talent’ Program; and the Wuhan Application
Foundation Frontier Project [grant number 2019020701011471].
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区移植4 区医学：研究与实验4 区细胞与组织工程
最新[2023]版：
大类|4 区医学
小类|4 区细胞与组织工程4 区医学：研究与实验4 区移植
JCR分区：
出版当年[2021]版：
Q2TRANSPLANTATIONQ3CELL & TISSUE ENGINEERINGQ3MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2TRANSPLANTATIONQ3CELL & TISSUE ENGINEERING
第一作者机构：[1]Department of Orthopaedics, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Orthopaedics, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China[*1]Department of Orthopaedics, Wuhan Third Hospital, Tongren Hospital of Wuhan University, No. 216, Guanshan Avenue, Hongshan District, Wuhan 430074, Hubei Province, China.
推荐引用方式(GB/T 7714)：
Liu Xiangzhong,Hu Jing,Ning Yu,et al.Aptamer Technology and Its Applications in Bone Diseases[J].CELL TRANSPLANTATION.2023,32:doi:10.1177/09636897221144949.
APA：
Liu Xiangzhong,Hu Jing,Ning Yu,Xu Haijia,Cai Hantao...&Li Zhanghua.(2023).Aptamer Technology and Its Applications in Bone Diseases.CELL TRANSPLANTATION,32,
MLA：
Liu Xiangzhong,et al."Aptamer Technology and Its Applications in Bone Diseases".CELL TRANSPLANTATION 32.(2023)
